Kt Corporation ADR Stock
Your prediction
Kt Corporation ADR Stock
We can see a decrease in the price for Kt Corporation ADR. Compared to yesterday it has lost -€0.300 (-1.860%).
Pros and Cons of Kt Corporation ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kt Corporation ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -1.860% | 0.637% | 0.637% | -7.059% | 0.000% | 41.071% | 23.438% |
| Freenet AG | 1.180% | -0.832% | 0.168% | -15.100% | -19.186% | 9.258% | 18.371% |
| Philippine Long Distance Telephone Company ADR | -0.600% | -0.595% | 3.727% | -14.359% | -7.222% | -19.712% | -16.500% |
| Telekom Austria AG | -1.180% | 0.000% | 0.599% | 8.039% | 12.249% | 50.224% | 32.283% |
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch